Company intelligence / Profile preview

Brooklyn ImmunoTherapeutics, Inc.

Brooklyn, New York, United Statesmarketscreener.com ↗

Ownership: Private
Development stage: Phase 2

Overview

In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. In a Phase 1b clinical trial in early stage breast cancer, IRX-2 was well-tolerated with no Grade 3 or 4 toxicities and showed encouraging signs of activity including upregulation of PD-L1.

Therapeutic areas: OncologyPulmonologyRare DiseasesHematology
Modalities: Cytokine-based therapyGene editing/cell therapymRNA cell engineering technology
Industry: Biotech

Drug pipeline

10 assets

citoplurikin

9 more assets in the full pipeline.

Request access →

Partnerships

Factor BioscienceNovellusProvidence Cancer InstituteJohn Theurer Cancer CenterUniversity of Miami

Beyond the preview

Go deeper on Brooklyn ImmunoTherapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Brooklyn ImmunoTherapeutics, Inc..

Explore the full profile